Skip to main content

Prediabetes & diabetes prevention

Browse the latest news, expert commentary, and educational content on prediabetes and diabetes prevention.

06-11-2021 | Glycemic control | News

Daily glycemic variability may contribute to aortic stiffness

Higher daily glucose variability is associated with greater aortic stiffness irrespective of average glucose levels, indicate findings from The Maastricht Study.

06-01-2021 | Atherosclerosis | News

Prediabetic, high normal HbA1c levels linked to subclinical atherosclerosis risk

The risk for subclinical atherosclerosis among people at low risk for cardiovascular death increases with increasing glycated hemoglobin levels and is raised even at levels below the prediabetes threshold, research shows.

05-16-2021 | Prediabetes | Conference coverage | News

‘Substantial gradient’ of cardiorenal risk at prediabetic glucose levels

The risk for adverse cardiorenal events begins to increase well below the glycemic level associated with type 2 diabetes, with the largest proportion of events occurring in people with prediabetic levels, shows a UK Biobank analysis.

04-16-2021 | Pathophysiology | News

Familial, sporadic type 1 diabetes are ‘overall similar’

Children with familial type 1 diabetes have different characteristics to those with sporadic diabetes at presentation, but longer-term outcomes are similar, say researchers.

03-09-2021 | Cardiovascular outcomes | News

Casual glucose level linked to CVD risk in absence of diabetes

A random blood glucose test in people without diabetes may provide a good indication of who has an increased risk for developing cardiovascular disease over the subsequent decade, a study suggests.

03-08-2021 | Immunotherapy | News

Anti-IL-21, liraglutide combination may warrant further investigation for early type 1 diabetes

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

03-05-2021 | Teplizumab | News

Teplizumab offers extended preservation of beta-cell function

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

03-02-2021 | Epidemiology | News

Signs of slowing diabetes incidence in higher-income countries

The incidence of diabetes in high- and middle-income countries may at last be stabilizing, or even in decline, say researchers.

02-23-2021 | Diabetes prevention | News

Stabilizing IGT for a time has significant long-term vascular benefits

Delaying progression from impaired glucose tolerance to type 2 diabetes reduces the risk for micro- and macrovascular complications, shows 24 years of follow-up of the Da Qing trial.

02-09-2021 | Older adults | News

Prediabetes a poor predictor of outcomes in older adults

Adults who develop prediabetes when older than 70 years are more likely to regress to normoglycemia or die of other causes than to progress to type 2 diabetes, research shows.

01-28-2021 | Diabetes prevention | News

Dapagliflozin may reduce diabetes risk in people with heart failure

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

12-21-2020 | Medications | News

Testosterone promising for diabetes prevention pending safety clarification

A randomized trial indicates that testosterone treatment among men with prediabetes or newly diagnosed type 2 diabetes significantly reduces the risk for them having type 2 diabetes 2 years later.

11-17-2020 | Empagliflozin | News

Favorable LV remodeling may contribute to empagliflozin benefits

The SGLT2 inhibitor empagliflozin may reverse adverse left ventricular remodeling in people who have heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, shows a randomized trial.

11-12-2020 | Diabetes prevention | News

Randomized type 2 diabetes prevention trial addresses knowledge gap

Lifestyle intervention significantly reduces the risk for type 2 diabetes in people who have prediabetes based on fasting plasma glucose or glycated hemoglobin measurements, show findings from a randomized trial.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits